Quality of life in cutaneous lymphoma patients: patient-reported outcomes

Quality of life in cutaneous lymphoma patients: patient-reported outcomes

VJHemOnc

1 year
110 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Pablo Ortiz, MD, PhD, of the University Hospital 12 of October, Madrid, Spain, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, on the quality of life of patients with cutaneous T-cell lymphoma. Prof. Ortiz expresses his concerns about clinical outcomes and patient expectations as a doctor, and highlights the need to gather more information on patient-reported outcomes to support the decision-making process of doctors.
Up Next Autoplay
Accelerating clinical trials in transplantation
Accelerating clinical trials in transplantation
Category: Acute Myelogenous Leukemia
1,218 Views
VJHemOnc 1 year
Whole genome sequencing opens door for targeted Waldenström’s therapy
Whole genome sequencing opens door for targeted Waldenström’s therapy
Category: Multiple Myeloma
821 Views
VJHemOnc 1 year
Updated POLLUX results for early relapsed myeloma patients
Updated POLLUX results for early relapsed myeloma patients
Category: Multiple Myeloma
935 Views
VJHemOnc 1 year
Targeting BCMA with bispecific antibodies in R/R myeloma
Targeting BCMA with bispecific antibodies in R/R myeloma
Category: Multiple Myeloma
969 Views
VJHemOnc 1 year
Monoclonal antibodies: current and future potential
Monoclonal antibodies: current and future potential
Category: General
767 Views
VJHemOnc 1 year
Plasma cell leukemia and extramedullary disease in multiple myeloma
Plasma cell leukemia and extramedullary disease in multiple myeloma
Category: General
275 Views
VJHemOnc 1 year
Judging the value of a clinical trial in hem-onc
Judging the value of a clinical trial in hem-onc
Category: General
54 Views
VJHemOnc 1 year
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Category: Multiple Myeloma
100 Views
VJHemOnc 1 year
Future treatment combinations for myeloma
Future treatment combinations for myeloma
Category: Melanoma and Skin Cancer
124 Views
VJHemOnc 1 year
Continuous vs. fixed duration therapy for multiple myeloma?
Continuous vs. fixed duration therapy for multiple myeloma?
Category: Multiple Myeloma
60 Views
VJHemOnc 1 year